65th American Society of Hematology Annual Meeting and Exposition (ASH 2023)

The addition of carfilzomib to lenalidomide and dexamethasone (KRd) improved outcomes in individuals with newly diagnosed fit or intermediate-fit multiple myeloma who are transplant ineligible (NTE NDMM) as opposed to Rd only in the phase III EMN20 trial.

Adding subcutaneous daratumumab to the three-drug regimen containing bortezomib, lenalidomide, and dexamethasone (VRd) appears to improve outcomes for transplant-eligible patients with newly diagnosed multiple myeloma (MM), with extended disease-free periods and increased depth of response, according to the phase III PERSEUS trial.